Self-Reported Medication Costs In Patients Receiving Sacral Neuromodulation For Overactive Bladder.
Value in Health(2015)
摘要
Many patients with overactive bladder (OAB) treated with anticholinergic medications (AM) continue to experience urinary symptoms; some may be candidates for specialized treatment including sacral neuromodulation (SNM). This analysis determined AM costs in OAB patients who were enrolled in the InSite study. Subjects who failed >1 AM and were candidates for SNM were enrolled in a prospective, multicenter trial. For patients receiving SNM, AM use was not permitted during the first 6 months. Thereafter patients could use medication if needed. Patient-reported AM cost at 12 months post-implant, based on an economic impact questionnaire inquiring about AM cost over the past 2 months, was compared to baseline. AM cost at baseline and 6 months for a separate cohort randomized to standard medical therapy (SMT) is included for comparison. Of 231 SNM patients, 207 had baseline and follow-up data, of which, 74 (35.7%) reported baseline AM costs >$0. Of 74, 4 (5.4%) reported AM costs at 12 months. Of 133 patients with $0 baseline cost, five (3.8%) reported AM cost >$0 at 12 months. Of the 207, the average cost/patient over a 2-month period was $178 at baseline and $14 at 12 months post-implant. Of 75 SMT patients, 68 had baseline and follow-up data, of which, 28 (41.2%) reported baseline AM costs >$0. Of 28, 19 (67.9%) reported AM costs at 6 months. Of 40 patients with $0 baseline cost, 11 (27.5%) reported AM cost >$0 at 6 months. Of the 68, the average cost/patient over a 2-month period was $176 at baseline and $218 at 6 months. For patients receiving SNM, the average AM cost/patient markedly decreased by 92.1% at 12 months. Reductions were not seen for patients receiving SMT, where the average AM cost per patient increased by 23.9% at 6 months.
更多查看译文
关键词
Overactive Bladder
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要